•   
  •   
  •   

Health & Fit Immune therapy scores big win against lung cancer in study

18:40  16 april  2018
18:40  16 april  2018 Source:   ap.org

Curing cancer ‘not a realistic goal,’ doctors focus on managing instead of curing disease

  Curing cancer ‘not a realistic goal,’ doctors focus on managing instead of curing disease "It’s been a big shift in the last 10 years with thinking about cancer in that way: instead of a cure, treat it like a chronic disease."Over the last five years, cancer research has seen the “greatest advances,” including a new approach to treating the complex disease as a “chronic disease,” instead of trying to cure it.

Research suggests that many more lung cancer patients may benefit from treatments that boost the immune system. It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers . In the study , Merck's Keytruda, given with standard

Research released on Monday, April 16, 2018 suggests that many more lung cancer patients may benefit from treatments that boost the immune system, which have scored some of their biggest wins until now in less common cancer types.

This 2015 photo made available by Merck shows the drug Keytruda. Research released on Monday, April 16, 2018 suggests that many more lung cancer patients may benefit from treatments that boost the immune system, which have scored some of their biggest wins until now in less common cancer types. Using one of these drugs _ Merck's Keytruda _ with usual chemotherapy extended survival for people newly diagnosed with the most common type of cancer that had spread beyond the lungs, one study found. (Michael Lund/Merck via AP) © The Associated Press This 2015 photo made available by Merck shows the drug Keytruda. Research released on Monday, April 16, 2018 suggests that many more lung cancer patients may benefit from treatments that boost the immune system, which have scored some of their biggest wins until now in less common cancer types. Using one of these drugs _ Merck's Keytruda _ with usual chemotherapy extended survival for people newly diagnosed with the most common type of cancer that had spread beyond the lungs, one study found. (Michael Lund/Merck via AP) CHICAGO — For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers.

Lung cancer risk drops substantially within five years of quitting smoking says new study

  Lung cancer risk drops substantially within five years of quitting smoking says new study New US research has found that quitting smoking can substantially reduce the risk of lung cancer within five years although also warns that ex-smokers still have a greater risk of the disease even years later. Carried out by researchers at Vanderbilt University Medical Center in Nashville, Tennessee, the study used data taken from the landmark Framingham Heart Study, which records the health information of residents in Framingham, Massachusetts, to look at high blood pressure and high cholesterol as key risk factors for cardiovascular disease, as well as tracking cancer outcomes.

It’s the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers . In the study , Merck’s Keytruda, given with standard All of these immune therapy treatments worked for only about half of patients, but that’s far better than chemo has done in the past.

For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer .

In the study, Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year. The results are expected to quickly set a new standard of care for about 70,000 patients each year in the United States whose lung cancer has already spread by the time it's found.

Another study found that an immunotherapy combo — the Bristol-Myers Squibb drugs Opdivo and Yervoy — worked better than chemo for delaying the time until cancer worsened in advanced lung cancer patients whose tumors have many gene flaws, as nearly half do. But the benefit lasted less than two months on average and it's too soon to know if the combo improves overall survival, as Keytruda did.

A cancer 'vaccine' is completely eliminating tumors in mice

  A cancer 'vaccine' is completely eliminating tumors in mice A new cancer treatment experiment that used immune stimulators to target tumors in mice had remarkably encouraging results. After injecting a combination of two immune boosters directly into solid mouse tumors, the research team said the vaccination eliminated all traces of the specifically targeted cancer from the animal's entire body — including metastases that were previously untreated."When we use these two agents together, we see the elimination of tumors all over the body," senior author of the study, Dr. Ronald Levy told the Stanford Medicine News Center.

For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer . It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers . In the study , Merck's Keytruda

It's the biggest win so far for immunotherapy, which has had much Research released on Monday, April 16, 2018 suggests that many more lung cancer patients may benefit from treatments that boost the immune system, which have scored some of … more.

All of these immune therapy treatments worked for only about half of patients, but that's far better than chemo has done in the past.

"We're not nearly where we need to be yet," said Dr. Roy Herbst, a Yale Cancer Center lung expert who had no role in the studies.

Results were discussed Monday at an American Association for Cancer Research conference in Chicago and published by the New England Journal of Medicine. The studies were sponsored by the drugmakers, and many study leaders and Herbst consult for the companies.

ABOUT THE DRUGS

Keytruda, Yervoy and Opdivo are called checkpoint inhibitors. They remove a cloak that some cancer cells have that hides them from the immune system. The drugs are given through IVs and cost about $12,500 a month.

Keytruda was approved last year as an initial treatment with chemo for the most common form of advanced lung cancer, but doctors have been leery to use it because that was based on a small study that did not show whether it prolongs life.

Is chemo obsolete? No, cancer experts say

  Is chemo obsolete? No, cancer experts say New cancer treatments usually only help a fraction of cancer patients A new immune therapy drug seemingly cures former President Jimmy Carter's melanoma. A patient with tumors all over her body is rescued from certain death by a new personalized treatment. CAR-T therapy reverses blood cancer in children.Cancer therapy is being transformed as immune therapies, targeted treatments based on DNA profiles and personalized treatments make stunning advances in some patients.

Research released on Monday, April 16, 2018 suggests that many more lung cancer patients may benefit from treatments — like Merck's Keytruda — that boost the immune system, which have scored some of their biggest wins until now in less common cancer types.

For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer .

The new study, led by Dr. Leena Gandhi of NYU's Perlmutter Cancer Center, gives that proof. In it, 616 patients were given chemo and some also received Keytruda. Those not given Keytruda were allowed to switch to it if their cancer worsened.

After one year, 69 percent of people originally assigned to Keytruda were alive versus 49 percent of the others — a result that experts called remarkable considering that the second group's survival was improved because half of them wound up switching.

How much it ultimately will extend life isn't known — more than half in the Keytruda group are still alive; median survival was just over 11 months for the others.

The Keytruda combo also delayed the time until cancer worsened — an average of nine months versus five months for the chemo-only group.

That's a big difference for such an advanced cancer, said Dr. Alice Shaw, a Massachusetts General Hospital lung cancer expert and one of the conference leaders. "This is really a pivotal study ... a new standard of care," said Shaw, who has no ties to the drugmakers.

Rates of serious side effects were similar, but twice as many in the Keytruda group dropped out because of them. More than 4 percent of that group developed lung inflammation and three patients died of it.

Study: Cancer Vaccine Cures 97 Percent of Tumors in Mice, Human Trials to Begin Soon

  Study: Cancer Vaccine Cures 97 Percent of Tumors in Mice, Human Trials to Begin Soon A new vaccine that cured 97 percent of cancerous tumors in mice has been approved for human trials.A new vaccine that cured 97 percent of cancerous tumors in mice has been approved for human trials.

Home » National News » Immune therapy scores big … CHICAGO (AP) — For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer .

For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer . It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers . In

THE COMPETITION

Dr. Matthew Hellmann of Memorial Sloan Kettering Cancer Center in New York led a study testing the Opdivo-Yervoy combo versus chemo in a slightly different group of newly diagnosed advanced lung cancer patients.

The study design was changed after it was underway to look at results according to patients' tumor mutation burden — a measure of how flawed their cancer genes are, according to a profiling test by Foundation Medicine. Medicare recently agreed to cover the $3,000 test for advanced cancers.

Of 679 patients, 299 had a high number of gene flaws in their tumors. In that group, survival without worsening of disease was 43 percent after one year for those on the immunotherapy drugs versus 13 percent of those on chemo. The immunotherapy drugs did not help people with fewer tumor gene flaws.

"We have a tool that helps us determine who are the patients that are most likely to benefit from this combination," Hellmann said.

The median time until cancer worsened was about 7 months on the immunotherapy drugs versus 5.5 months for chemo. Serious side effects were a little more common in the chemo group.

Another rival, Genentech, recently announced that its checkpoint inhibitor, Tecentriq, improved survival in a study similar to the one testing Keytruda. Details are expected in a couple months.

'Artificial mole' could warn of cancer: study

  'Artificial mole' could warn of cancer: study Swiss scientists have developed an experimental skin implant that darkens like a mole when it detects subtle changes in the body that may be an early warning sign of cancer, a study said Wednesday. The implant, or "biomedical tattoo," as researchers call it, has been tested in lab animals, lasts about a year and recognizes the four most common types of cancer: prostate, lung, colon and breast cancer.It works by reacting to the level of calcium in the blood, which rises when a tumor is developing. About 40 percent of cancers could theoretically be detected this way, researchers said.

It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers . In the study , Merck's Keytruda, given with standard All of these immune therapy treatments worked for only about half of patients, but that's far better than chemo has done in the past.

CHICAGO — For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer . It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers .

Marilynn Marchione can be followed on Twitter: @MMarchioneAP

Gallery: 7 signs of lung cancer you might be ignoring (courtesy Reader's Digest) Coughing up blood: 'Coughing up blood is never a good sign. Right then and there, go see your doctor,' says Raja Flores, MD, professor and chairman of thoracic surgery at Icahn School of Medicine at Mount Sinai in New York City. Although cancer may not necessarily be the cause of your bloody coughs, you should definitely get tested, he says. These are 15 cancer symptoms women are most likely to ignore. 7 signs of lung cancer you might be ignoring

The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

New Drug Could Prevent Cancer Cells Spreading .
Preventing cancer from spreading is essential to saving lives. Scientists have discovered compound that could freeze cancer cells in their tracks and stop them from spreading, potentially making them easier to kill, according to research published in the journal Nature Communications.While treating the disease requires destroying cancerous cells, halting their spread around the body—a process known as metastasis—is just as important.

—   Share news in the SOC. Networks

Topical videos:

This is interesting!